
  
    
      
        Introduction_NNP
        Rheumatoid_NNP arthritis_NN (_( RA_NNP )_) is_VBZ a_DT significant_JJ ,_, chronic_JJ
        disease_NN that_WDT afflicts_VBZ 1_CD %_NN of_IN the_DT general_JJ population_NN in_IN most_JJS
        countries_NNS [_NN 1_CD ]_NN ._. Joint_NNP damage_NN typically_RB occurs_VBZ before_IN
        patients_NNS are_VBP diagnosed_VBN ,_, and_CC most_JJS of_IN the_DT joint_JJ destruction_NN
        occurs_VBZ within_IN the_DT first_JJ 2_CD years_NNS of_IN diagnosis_NN [_NN 2_CD ]_NN ._.
        Therapeutic_NNP drugs_NNS such_JJ as_IN sulfasalazine_NN and_CC methotrexate_NN
        (_( MTX_NNP )_) only_RB slow_VB the_DT progression_NN of_IN the_DT disease_NN ,_, suggesting_VBG
        that_IN these_DT drugs_NNS fail_VBP to_TO adequately_RB quell_VB the_DT underlying_VBG
        pathophysiology_NN of_IN RA_NNP [_NN 3_CD ]_NN ._.
        Tumor_NNP necrosis_NNS factor_NN alpha_NN (_( TNF-α_NNP )_) is_VBZ elevated_VBD in_IN sera_NN
        and_CC synovial_NN fluid_NN of_IN patients_NNS with_IN RA_NNP ,_, suggesting_VBG that_IN it_PRP
        may_MD play_VB a_DT role_NN in_IN the_DT pathology_NN of_IN the_DT disease_NN [_NN 4_CD ]_NN ._.
        Soluble_NNP TNF-α_NNP receptor_NN or_CC neutralizing_VBG antibodies_NNS against_IN
        TNF-α_NNP have_VBP been_VBN shown_VBN to_TO prevent_VB collagen-induced_JJ arthritis_NN
        in_IN mice_NNS [_NN 5_CD 6_CD ]_NN ._. Furthermore_RB ,_, a_DT human_JJ TNF-α_NNP (_( hTNF-α_JJ )_)
        transgenic_JJ mouse_NN (_( Tg_NNP 197_CD )_) develops_VBZ a_DT chronic_JJ ,_, progressive_JJ
        polyarthritis_NNS with_IN histologic_JJ features_NNS in_IN common_JJ with_IN RA_NNP [_NN
        7_CD ]_NN ._. Weight_NNP loss_NN and_CC joint_NN swelling_VBG in_IN these_DT mice_NNS are_VBP
        correlated_JJ with_IN expression_NN of_IN hTNF-α_JJ mRNA_NN in_IN the_DT joints_NNS [_NN 7_CD
        ]_NN and_CC hTNF-α_JJ concentrations_NNS in_IN the_DT serum_NN [_NN 8_CD 9_CD ]_NN ._.
        Previously_RB ,_, Keffer_NNP 
        et_CC al_NN ._. [_NN 7_CD ]_NN showed_VBD that_DT progression_NN
        of_IN disease_NN in_IN these_DT mice_NNS could_MD be_VB prevented_VBN by_IN treatment_NN
        with_IN anti-_NN TNF-α_NNP monoclonal_NN antibody_NN (_( mAb_NN )_) ._. In_IN this_DT study_NN ,_,
        we_PRP utilized_JJ the_DT Tg_NNP 197_CD mouse_NN model_NN to_TO further_VB assess_VB whether_IN
        anti-_NN TNF-α_NNP treatment_NN can_MD ameliorate_NN established_VBD disease_NN in_IN
        both_DT young_JJ and_CC aged_VBN mice_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Tg_NNP 197_CD mice_NNS and_CC anti-_NN TNF-α_NNP mAb_NN treatment_NN
          Heterozygous_NNP Tg_NNP 197_CD transgenic_JJ mice_NNS ,_, obtained_VBN from_IN Dr_NNP
          George_NNP Kollias_NNP (_( Hellenic_NNP Pasteur_NNP Institute_NNP ,_, Athens_NNP ,_,
          Greece_NNP )_) [_NN 7_CD ]_NN ,_, were_VBD identified_VBN by_IN PCR_NNP analysis_NN using_VBG
          primers_NNS to_TO the_DT 3_CD '_POS -_: modified_VBN hTNF-α_JJ gene_NN ._. Two_CD experimental_JJ
          groups_NNS of_IN 25_CD mice_NNS were_VBD used_VBN ._. '_POS Young_NNP mice_NNS '_POS were_VBD enrolled_VBN
          into_IN the_DT study_NN when_WRB they_PRP developed_VBD clinical_JJ signs_NNS of_IN
          arthritis_NN at_IN 7_CD or_CC 8_CD weeks_NNS of_IN age_NN ._. A_DT second_JJ group_NN of_IN mice_NNS
          was_VBD maintained_VBN disease-free_JJ with_IN 10_CD mg_NN /_NN kg_NN of_IN anti-_NN TNF-α_NNP
          mAb_NN weekly_JJ starting_NN at_IN 4_CD weeks_NNS of_IN age_NN ;_: when_WRB they_PRP reached_VBD
          24_CD weeks_NNS of_IN age_NN ,_, the_DT treatment_NN was_VBD stopped_VBN and_CC these_DT
          '_POS aged_VBN mice_NNS '_POS were_VBD allowed_VBN to_TO develop_VB arthritis_NN before_IN they_PRP
          were_VBD enrolled_VBN into_IN the_DT study_NN ._. The_DT enrollment_NN criteria_NNS for_IN
          both_DT young_JJ and_CC aged_VBN mice_NNS required_VBD them_PRP to_TO have_VB a_DT clinical_JJ
          score_NN of_IN at_IN least_JJS 2_CD on_IN two_CD limbs_NNS ._. The_DT experimental_JJ
          protocols_NNS were_VBD approved_VBN by_IN Centocor_NNP 's_POS Institutional_NNP
          Animal_NNP Care_NNP and_CC Use_NNP Committee_NNP ._.
          The_DT murine_NN anti-_NN TNF-α_NNP mAb_NN used_VBN in_IN this_DT study_NN binds_NNS
          with_IN high_JJ affinity_NN to_TO hTNF-α_JJ and_CC prevents_VBZ binding_VBG to_TO the_DT
          TNF_NNP receptor_NN [_NN 10_CD ]_NN ._. Anti-_NNP TNF-α_NNP mAb_NN was_VBD administered_VBN by_IN
          intraperitoneal_NN injection_NN at_IN 10_CD mg_NN /_NN kg_NN weekly_JJ and_CC the_DT
          animals_NNS in_IN the_DT control_NN group_NN received_VBD weekly_JJ injections_NNS
          of_IN saline_NN ._.
        
        
          Clinical_NNP scores_NNS
          Clinical_NNP scores_NNS were_VBD based_VBN on_IN a_DT previously_RB described_VBN
          scoring_VBG system_NN [_NN 11_CD ]_NN modified_VBN as_IN follows_VBZ :_: 0_CD (_( normal_JJ )_) ,_, 1_CD
          (_( edema_NN or_CC distortion_NN of_IN paw_NN or_CC ankle_NN joints_NNS )_) ,_, 2_CD
          (_( distortion_NN of_IN paw_NN and_CC ankle_NN joints_NNS )_) ,_, or_CC 3_CD (_( ankylosis_NNS of_IN
          wrist_NN or_CC ankle_NN joints_NNS )_) ._. The_DT sum_NN of_IN all_DT four_CD paws_NNS was_VBD
          scored_VBN weekly_JJ ,_, with_IN a_DT maximum_NN possible_JJ score_NN of_IN 12_CD per_IN
          mouse_NN ._.
        
        
          Histologic_NNP processing_NN of_IN joints_NNS
          Specimens_NNP were_VBD processed_VBN and_CC scored_VBN as_IN described_VBN
          previously_RB [_NN 12_CD 13_CD ]_NN and_CC in_IN the_DT supplementary_JJ
          material_NN ._.
        
        
          ELISA_NNP assay_NN
          Serum_NNP samples_NNS were_VBD separated_JJ from_IN whole_JJ blood_NN ,_, which_WDT
          was_VBD collected_VBN by_IN intracardiac_NN puncture_NN at_IN baseline_NN and_CC at_IN
          3_CD ,_, 6_CD ,_, and_CC 16_CD weeks_NNS post-treatment_JJ ._. Serum_NNP levels_NNS of_IN hTNF-α_JJ
          were_VBD determined_VBN by_IN ELISA_NNP at_IN a_DT 1_CD :_: 2_CD dilution_NN according_VBG to_TO
          the_DT manufacturer_NN 's_POS instructions_NNS (_( Biosource_NNP International_NNP ,_,
          Camarillo_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          RNA_NNP isolation_NN and_CC RNase_NNP protection_NN assay_NN
          Samples_NNP were_VBD prepared_VBN as_IN described_VBN in_IN the_DT
          Supplementary_NNP material_NN and_CC analyzed_VBD in_IN an_DT RNase_NNP
          protection_NN assay_NN according_VBG to_TO the_DT manufacturer_NN 's_POS
          instructions_NNS (_( PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          All_DT data_NNS are_VBP expressed_VBN as_IN means_VBZ ±_NN standard_JJ deviation_NN
          unless_IN noted_VBD otherwise_RB ._. Statistical_NNP significance_NN was_VBD
          tested_VBN using_VBG analysis_NN of_IN variance_NN for_IN multiple_JJ groups_NNS ._. If_IN
          significant_JJ differences_NNS were_VBD found_VBN ,_, pair-wise_JJ testing_NN was_VBD
          performed_VBN using_VBG Tukey_NNP 's_POS test_NN ._. The_DT level_NN of_IN significance_NN
          for_IN all_DT comparisons_NNS was_VBD set_VBN at_IN 
          P_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Amelioration_NNP of_IN established_VBN polyarthritis_NNS by_IN
          treatment_NN with_IN anti-_NN TNF-α_NNP mAb_NN
          Increased_VBN cartilage_NN turnover_NN and_CC repair_NN in_IN response_NN to_TO
          insult_VB has_VBZ been_VBN observed_VBN in_IN young_JJ mice_NNS ,_, whereas_IN aged_VBN mice_NNS
          show_NN decreased_VBD cartilage_NN turnover_NN after_IN closure_NN of_IN the_DT
          growth_NN plate_NN [_NN 14_CD ]_NN ._. Therefore_RB ,_, anti-_NN TNF-α_NNP treatment_NN was_VBD
          evaluated_VBN in_IN both_DT young_JJ (_( 7_CD -_: 8_CD -_: week-old_JJ )_) and_CC aged_VBN
          (_( 27_CD -_: 28_CD -_: week-old_JJ )_) Tg_NNP 197_CD mice_NNS with_IN established_VBN arthritis_NN ._.
          The_DT mean_JJ clinical_JJ arthritis_NN score_NN at_IN baseline_NN was_VBD 6_CD (_( Fig_NNP ._.
          1_LS )_) ,_, indicating_VBG arthritis_NN was_VBD established_VBN at_IN the_DT
          commencement_NN of_IN treatment_NN ._. The_DT clinical_JJ arthritis_NN score_NN
          increased_VBN progressively_RB in_IN the_DT saline-treated_JJ group_NN and_CC
          these_DT mice_NNS were_VBD humanely_RB killed_VBN at_IN 6_CD weeks_NNS ._. In_IN contrast_NN ,_,
          the_DT clinical_JJ arthritic_JJ score_NN was_VBD markedly_RB decreased_VBN in_IN
          the_DT groups_NNS ,_, both_DT young_JJ and_CC aged_VBN ,_, treated_VBN with_IN anti-_NN TNF-α_NNP ,_,
          indicating_VBG a_DT marked_VBN suppression_NN of_IN their_PRP$ arthritic_JJ
          symptoms_NNS (_( Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. Mice_NNS in_IN the_DT saline-treated_JJ group_NN
          progressively_RB lost_VBD weight_NN ,_, whereas_IN mice_NNS in_IN the_DT anti-_NN TNF-α_NNP
          group_NN showed_VBD a_DT significant_JJ weight_NN gain_NN throughout_IN the_DT
          study_NN (_( see_VB Supplementary_NNP Fig_NNP ._. 1_LS )_) ._. The_DT arthritic_JJ score_NN
          (_( weeks_NNS 1_CD to_TO 16_CD post-treatment_JJ ;_: Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) and_CC weight_NN
          gain_NN (_( weeks_NNS 5_CD to_TO 16_CD post-treatment_JJ ;_: Supplementary_NNP Fig_NNP ._. 1_LS )_)
          in_IN the_DT group_NN treated_VBN with_IN anti-_NN TNF-α_NNP were_VBD significantly_RB
          improved_VBN in_IN comparison_NN with_IN the_DT saline-treated_JJ group_NN in_IN
          both_DT young_JJ and_CC aged_VBN mice_NNS ._. More_RBR importantly_RB ,_, the_DT arthritic_JJ
          scores_NNS for_IN the_DT group_NN treated_VBN with_IN anti-_NN TNF-α_NNP were_VBD
          significantly_RB improved_VBN in_IN comparison_NN with_IN the_DT baseline_NN
          score_NN from_IN weeks_NNS 4_CD through_IN 16_CD in_IN both_DT young_JJ and_CC aged_VBN mice_NNS
          (_( Fig_NNP ._. 1_LS a_DT ,_, 1_CD b_SYM )_) ._. These_DT results_NNS indicate_VBP that_DT disease_NN
          progression_NN was_VBD not_RB just_RB prevented_VBN but_CC was_VBD reversed_VBN
          following_VBG anti-_NN TNF-α_NNP treatment_NN ._.
        
        
          Effects_NNPS of_IN treatment_NN with_IN anti-_NN TNF-α_NNP mAb_NN on_IN joint_JJ
          histopathology_NN
          All_DT joints_NNS were_VBD scored_VBN in_IN a_DT blinded_JJ fashion_NN for_IN
          synovitis_NNS ,_, bone_NN erosions_NNS ,_, and_CC cartilage_NN degradation_NN using_VBG
          a_DT predefined_JJ scoring_VBG system_NN ._. The_DT mean_JJ histologic_JJ scores_NNS
          for_IN each_DT treatment_NN group_NN at_IN various_JJ time_NN points_NNS are_VBP shown_VBN
          in_IN Fig_NNP ._. 2_LS ._. Saline_NNP treatment_NN was_VBD followed_VBN by_IN increased_VBN
          histologic_JJ scores_NNS for_IN synovitis_NNS ,_, bone_NN erosions_NNS ,_, and_CC
          cartilage_NN damage_NN relative_JJ to_TO that_DT observed_VBD at_IN baseline_NN ._.
          Anti-_NNP TNF-α_NNP treatment_NN for_IN 6_CD weeks_NNS significantly_RB reduced_VBD
          all_DT three_CD histologic_JJ scores_NNS relative_JJ to_TO the_DT baseline_NN
          score_NN in_IN young_JJ mice_NNS (_( Fig_NNP ._. 2_LS )_) and_CC two_CD of_IN the_DT three_CD
          histologic_JJ scores_NNS in_IN aged_VBN mice_NNS (_( Supplementary_NNP Fig_NNP ._. 2_LS )_) ._.
          After_IN 16_CD weeks_NNS of_IN anti-_NN TNF-α_NNP treatment_NN ,_, synovial_NN
          inflammation_NN and_CC bone_NN erosions_NNS were_VBD almost_RB completely_RB
          resolved_VBN in_IN both_DT young_JJ and_CC aged_VBN mice_NNS ,_, and_CC a_DT significant_JJ
          reduction_NN in_IN cartilage_NN degradation_NN in_IN comparison_NN with_IN
          baseline_NN was_VBD maintained_VBN in_IN young_JJ mice_NNS ._. Cartilage_NNP
          degradation_NN in_IN aged_VBN mice_NNS treated_VBN with_IN anti-_NN TNF-α_NNP was_VBD
          similar_JJ to_TO that_DT at_IN the_DT baseline_NN measurement_NN and_CC
          significantly_RB lower_JJR than_IN that_DT in_IN the_DT saline_NN treatment_NN
          group_NN (_( Supplementary_NNP Fig_NNP ._. 2_LS )_) ._.
          Representative_NNP tissue_NN sections_NNS of_IN the_DT ankle_NN joints_NNS
          from_IN young_JJ mice_NNS are_VBP shown_VBN in_IN Fig_NNP ._. 3_LS ._. Evidence_NN of_IN
          arthritic_JJ disease_NN was_VBD readily_RB observed_VBN at_IN baseline_NN (_( Fig_NNP ._.
          3_LS a_DT ,_, 3_CD b_SYM )_) ,_, and_CC the_DT disease_NN continued_VBD to_TO progress_VB in_IN
          saline-treated_JJ mice_NNS at_IN 6_CD weeks_NNS ,_, with_IN increased_VBN cell_NN
          proliferation_NN and_CC inflammatory_JJ cell_NN infiltration_NN ,_, erosion_NN
          of_IN cartilage_NN and_CC bone_NN ,_, and_CC loss_NN of_IN proteoglycan_NN from_IN the_DT
          cartilage_NN (_( Fig_NNP ._. 3_LS c_SYM ,_, 3_CD d_SYM )_) ._. However_RB ,_, after_IN 6_CD weeks_NNS of_IN
          anti-_NN TNF-α_NNP treatment_NN ,_, improvements_NNS in_IN all_DT
          histopathological_JJ parameters_NNS were_VBD observed_VBN with_IN both_DT
          staining_VBG procedures_NNS (_( Fig_NNP ._. 3_LS e_SYM ,_, 3_CD f_SYM )_) ._. No_DT visible_JJ evidence_NN of_IN
          bone_NN or_CC cartilage_NN erosion_NN was_VBD observed_VBN and_CC all_DT signs_NNS of_IN
          cellular_JJ proliferation_NN and_CC infiltration_NN disappeared_VBD ._. The_DT
          proteoglycan_NN content_NN of_IN the_DT cartilage_NN was_VBD notably_RB
          improved_VBN ._. Extended_NNP treatment_NN with_IN anti-_NN TNF-α_NNP (_( for_IN 16_CD
          weeks_NNS )_) maintained_VBN normal_JJ joint_JJ architecture_NN (_( data_NNS not_RB
          shown_VBN )_) ._. These_DT results_NNS demonstrate_VBP that_IN blocking_VBG hTNF-α_JJ
          reverses_VBZ joint_JJ inflammation_NN and_CC promotes_VBZ joint_JJ healing_NN in_IN
          this_DT model_NN of_IN polyarthritis_NNS ._.
        
        
          Inhibition_NNP of_IN TNF-α_NNP and_CC other_JJ proinflammatory_NN
          cytokines_NNS
          To_TO define_VB the_DT underlying_VBG mechanisms_NNS by_IN which_WDT
          anti-_NN TNF-α_NNP mAb_NN ameliorated_JJ joint_JJ inflammation_NN and_CC
          structural_JJ damage_NN ,_, the_DT levels_NNS of_IN various_JJ proinflammatory_NN
          mediators_NNS were_VBD examined_VBN ._. First_LS ,_, circulating_VBG hTNF-α_JJ levels_NNS
          as_IN detected_VBN by_IN ELISA_NNP were_VBD more_JJR than_IN halved_VBN as_RB early_RB as_IN 3_CD
          weeks_NNS and_CC the_DT reduction_NN was_VBD sustained_VBN for_IN 16_CD weeks_NNS after_IN
          treatment_NN with_IN anti-_NN TNF-α_NNP mAb_NN in_IN comparison_NN with_IN
          saline-treated_JJ animals_NNS (_( Fig_NNP ._. 4_LS a_DT )_) ._. In_IN addition_NN ,_, murine_NN
          IL-_NNP 6_CD ,_, IL-_NNP 1_CD β_NN ,_, and_CC IFN-γ_NNP mRNA_NN ,_, which_WDT are_VBP expressed_VBN in_IN the_DT
          arthritic_JJ joint_JJ tissues_NNS ,_, were_VBD clearly_RB diminished_VBN
          following_VBG anti-_NN TNF-α_NNP treatment_NN when_WRB total_JJ joint_JJ RNA_NNP was_VBD
          examined_VBN by_IN RNase_NNP protection_NN assays_NNS (_( see_VB Supplementary_NNP
          Fig_NNP ._. 3_LS )_) ._. When_WRB the_DT levels_NNS of_IN murine_NN IL-_NNP 6_CD ,_, IL-_NNP 1_CD β_NN ,_, and_CC IFN-γ_NNP
          mRNA_NN were_VBD standardized_JJ to_TO glyceraldehyde-_NN 3_CD -_: phosphate_NN
          dehydrogenase_NN (_( GAPDH_NNP )_) (_( Fig_NNP ._. 4_LS b_SYM ,_, 4_CD c_SYM ,_, 4_CD d_SYM )_) ,_, a_DT 2_CD -_: 3_CD -_: fold_VB
          reduction_NN in_IN murine_NN IL-_NNP 6_CD and_CC IFN-γ_NNP was_VBD observed_VBN in_IN the_DT
          aged_VBN animals_NNS treated_VBN with_IN anti-_NN TNF-α_NNP in_IN comparison_NN with_IN
          those_DT treated_VBN with_IN saline_NN at_IN 6_CD weeks_NNS post-treatment_JJ (_( Fig_NNP ._.
          4_LS b_SYM ,_, 4_CD c_SYM )_) ._. Interestingly_RB ,_, local_JJ expression_NN of_IN murine_NN TNF-α_NNP
          mRNA_NN was_VBD not_RB affected_VBN by_IN treatment_NN with_IN anti-_NN TNF-α_NNP
          antibodies_NNS ,_, suggesting_VBG that_IN hTNF-α_JJ plays_VBZ a_DT crucial_JJ role_NN
          in_IN the_DT pathogenesis_NNS of_IN arthritis_NN in_IN this_DT model_NN ._.
        
      
      
        Discussion_NNP
        Currently_RB ,_, MTX_NNP is_VBZ the_DT most_RBS widely_RB used_VBN disease-modifying_JJ
        antirheumatic_JJ drug_NN for_IN the_DT treatment_NN of_IN RA_NNP ._. However_RB ,_, MTX_NNP
        treatment_NN rarely_RB results_VBZ in_IN complete_JJ disease_NN remission_NN [_NN 15_CD
        ]_NN and_CC only_RB slows_VBZ the_DT progression_NN of_IN joint_JJ erosion_NN [_NN 16_CD ]_NN ._.
        In_IN addition_NN ,_, long-term_JJ treatment_NN with_IN MTX_NNP is_VBZ associated_VBN
        with_IN pulmonary_JJ [_NN 17_CD ]_NN and_CC liver_NN toxicities_NNS [_NN 18_CD ]_NN and_CC other_JJ
        side_NN effects_NNS ._. Therefore_RB ,_, a_DT treatment_NN option_NN that_IN
        facilitates_NNS reversal_NN of_IN joint_JJ damage_NN and_CC has_VBZ longer_JJR
        effectiveness_NN and_CC fewer_JJR side_NN effects_NNS is_VBZ desirable_JJ ._.
        Experimental_NNP arthritis_NN models_NNS have_VBP contributed_VBN to_TO the_DT
        basic_JJ understanding_NN of_IN joint_JJ disease_NN and_CC to_TO the_DT development_NN
        of_IN effective_JJ antiarthritic_JJ agents_NNS [_NN 19_CD ]_NN ._. Several_JJ models_NNS
        have_VBP been_VBN used_VBN to_TO mimic_VB human_JJ RA_NNP ,_, ranging_VBG from_IN immunization_NN
        with_IN cartilage_NN components_NNS to_TO infection_NN with_IN joint_JJ trophic_JJ
        organisms_NNS [_NN 20_CD 21_CD ]_NN ._. Blocking_NNP TNF-α_NNP [_NN 6_CD 22_CD ]_NN or_CC IL-_NNP 1_CD [_NN 23_CD
        24_CD ]_NN in_IN these_DT models_NNS has_VBZ routinely_RB shown_VBN benefit_NN ,_, although_IN
        some_DT questions_NNS remain_VBP regarding_VBG the_DT role_NN of_IN these_DT cytokines_NNS
        in_IN mitigating_JJ joint_JJ inflammation_NN versus_CC preventing_VBG
        cartilage_NN degradation_NN and_CC bone_NN erosion_NN [_NN 25_CD ]_NN ._.
        Using_VBG the_DT Tg_NNP 197_CD mice_NNS ,_, we_PRP have_VBP shown_VBN that_DT maintenance_NN
        anti-_NN TNF-α_NNP therapy_NN ,_, initiated_VBN after_IN joint_JJ inflammation_NN and_CC
        erosions_NNS have_VBP occurred_VBN ,_, allows_VBZ damaged_JJ joints_NNS to_TO heal_VB ._.
        Specifically_RB ,_, anti-_NN TNF-α_NNP mAb_NN proved_VBD equally_RB effective_JJ in_IN
        reversing_VBG joint_JJ synovitis_NNS and_CC erosions_NNS both_DT in_IN young_JJ mice_NNS ,_,
        where_WRB an_DT active_JJ repair_NN process_NN to_TO damage_VB occurs_VBZ ,_, and_CC aged_VBN
        mice_NNS ,_, where_WRB the_DT repair_NN process_NN has_VBZ relatively_RB slowed_VBN ._.
        However_RB ,_, the_DT repair_NN of_IN cartilage_NN damage_NN was_VBD different_JJ
        between_IN young_JJ and_CC aged_VBN mice_NNS ._. Cartilage_NNP in_IN young_JJ mice_NNS
        treated_VBN with_IN anti-_NN TNF-α_NNP was_VBD significantly_RB improved_VBN relative_JJ
        to_TO saline-treated_JJ and_CC baseline_NN mice_NNS ._. By_IN comparison_NN ,_,
        treatment_NN of_IN aged_VBN mice_NNS with_IN anti-_NN TNF-α_NNP prevented_VBD further_JJ
        cartilage_NN damage_NN but_CC did_VBD not_RB improve_VB histological_JJ scores_NNS
        relative_JJ to_TO baseline_NN values_NNS ._. Mechanistically_NNP ,_, the_DT
        therapeutic_JJ effect_NN of_IN anti-_NN TNF-α_NNP appears_VBZ to_TO be_VB due_JJ to_TO
        either_CC neutralization_NN of_IN soluble_JJ hTNF-α_JJ or_CC inhibition_NN of_IN
        hTNF-α_JJ production_NN in_IN the_DT diseased_JJ joint_NN ._. Additionally_RB ,_,
        other_JJ proinflammatory_NN cytokine_NN mRNAs_NNS were_VBD decreased_VBN in_IN the_DT
        local_JJ diseased_JJ tissues_NNS either_CC through_IN suppression_NN of_IN
        inflammatory_JJ cell_NN infiltration_NN or_CC inhibition_NN of_IN cytokine_NN
        production_NN ._. Moreover_RB ,_, anti-_NN TNF-α_NNP treatment_NN resulted_VBD in_IN a_DT
        modest_JJ inhibition_NN of_IN murine_NN IL-_NNP 1_CD β_NN production_NN in_IN the_DT
        diseased_JJ joint_NN ,_, which_WDT is_VBZ consistent_JJ with_IN previous_JJ findings_NNS
        that_WDT anti-_NN TNF-α_NNP antibody_NN inhibits_NNS the_DT generation_NN of_IN IL-_NNP 1_CD in_IN
        collagen-induced_JJ arthritis_NN and_CC IL-_NNP 1_CD ,_, IL-_NNP 6_CD ,_, and_CC IL-_NNP 8_CD in_IN
        rheumatoid_NN synovial_NN cultures_NNS [_NN 26_CD 27_CD ]_NN ._. Our_PRP$ study_NN provides_VBZ
        preclinical_JJ evidence_NN supporting_VBG the_DT use_NN of_IN anti-_NN TNF-α_NNP mAb_NN
        in_IN ameliorating_VBG arthritic_JJ pathology_NN ._.
        The_DT progressive_JJ arthritis_NN observed_VBD in_IN Tg_NNP 197_CD mice_NNS is_VBZ
        similar_JJ to_TO the_DT pathology_NN in_IN patients_NNS with_IN RA_NNP ._. Recent_JJ
        clinical_JJ data_NNS indicate_VBP that_IN the_DT blockade_NN of_IN TNF-α_NNP
        significantly_RB reduces_VBZ the_DT signs_NNS and_CC symptoms_NNS of_IN RA_NNP [_NN 28_CD 29_CD
        ]_NN and_CC inhibits_NNS the_DT progression_NN of_IN structural_JJ damage_NN [_NN 30_CD 31_CD
        ]_NN ._. It_PRP remains_VBZ to_TO be_VB seen_VBN whether_IN extended_VBN anti-_NN TNF-α_NNP
        therapy_NN might_MD permit_VB regeneration_NN of_IN articular_NN cartilage_NN
        and_CC bone_NN in_IN established_VBN human_JJ disease_NN ,_, where_WRB multiple_JJ
        etiological_JJ pathways_NNS may_MD contribute_VB to_TO the_DT RA_NNP disease_NN
        syndrome_NN [_NN 32_CD 33_CD ]_NN ._. Nevertheless_RB ,_, it_PRP is_VBZ likely_JJ that_IN much_JJ
        of_IN the_DT RA_NNP pathology_NN involves_VBZ TNF-α_NNP activation_NN ,_, and_CC the_DT
        results_NNS from_IN the_DT Tg_NNP 197_CD model_NN provide_VBP a_DT sound_NN scientific_JJ
        rationale_NN for_IN the_DT therapeutic_JJ benefits_NNS observed_VBD following_VBG
        anti-_NN TNF-α_NNP treatment_NN in_IN RA_NNP patients_NNS ._.
      
      
        Conclusion_NNP
        Progression_NNP of_IN established_VBN polyarthritis_NNS in_IN the_DT Tg_NNP 197_CD
        hTNF-α_JJ transgenic_JJ mouse_NN can_MD be_VB reversed_VBN by_IN treatment_NN with_IN
        anti-_NN TNF-α_NNP mAb_NN ,_, as_IN shown_VBN by_IN significant_JJ improvement_NN in_IN
        clinical_JJ and_CC histological_JJ scores_NNS ._.
      
      
        Abbreviations_NNP
        Anti-_NNP TNF-α_NNP =_SYM anti-tumor_JJ necrosis_NNS factor_NN alpha_NN ;_: ELISA_NNP =_SYM
        enzyme-linked_JJ immunosorbent_NN assay_NN ;_: hTNF-α_JJ =_SYM human_JJ tumor_NN
        necrosis_NNS factor_NN alpha_NN ;_: IFN_NNP =_SYM interferon_NN ;_: IL_NNP =_SYM interleukin_NN ;_:
        mAb_NN =_SYM monoclonal_NN antibody_NN ;_: mRNA_NN =_SYM messenger_NN ribonucleic_JJ
        acid_NN ;_: MTX_NNP =_SYM methotrexate_NN ;_: PCR_NNP =_SYM polymerase_NN chain_NN reaction_NN ;_:
        RA_NNP =_SYM rheumatoid_NN arthritis_NN ;_: TNF-α_NNP =_SYM tumor_NN necrosis_NNS factor_NN
        alpha_NN ._.
      
      
        Supplementary_NNP material_NN
        
          Supplementary_NNP materials_NNS and_CC methods_NNS
          
            Histologic_NNP processing_NN of_IN joints_NNS
            Joint_NNP tissues_NNS from_IN wrists_NNS ,_, ankles_NNS ,_, elbows_NNS ,_, and_CC knees_NNS
            were_VBD fixed_VBN in_IN 10_CD %_NN buffered_JJ formalin_NN overnight_JJ ,_,
            decalcified_JJ in_IN 10_CD %_NN formic_JJ acid_NN for_IN 18_CD days_NNS ,_, dehydrated_JJ ,_,
            and_CC then_RB embedded_VBN in_IN paraffin_NN ._. Specimens_NNP were_VBD cut_VBN
            longitudinally_RB to_TO the_DT midline_NN ,_, and_CC 5_CD -_: m_NN sections_NNS mounted_VBD
            for_IN staining_VBG with_IN hematoxylin_NN and_CC eosin_NN or_CC toluidine_NN
            blue_JJ ._. Joint_NNP sections_NNS stained_JJ with_IN hematoxylin_NN and_CC eosin_NN
            were_VBD scored_VBN for_IN synovitis_NNS and_CC bone_NN erosions_NNS ,_, as_IN
            described_VBN elsewhere_RB [_NN 12_CD 13_CD ]_NN ._. Sections_NNP stained_JJ with_IN
            toluidine_NN blue_NN were_VBD scored_VBN for_IN cartilage_NN degradation_NN
            (_( 0_CD ,_, normal_JJ staining_VBG ;_: 1_CD ,_, some_DT loss_NN of_IN staining_VBG ;_: 2_CD ,_,
            moderate_JJ loss_NN of_IN staining_VBG ;_: 3_CD ,_, weak_JJ staining_VBG ;_: 4_CD ,_, very_RB
            weak_JJ staining_VBG ;_: 5_CD ,_, no_DT visible_JJ staining_VBG )_) ._. Specimens_NNP were_VBD
            examined_VBN using_VBG light_JJ microscopy_NN and_CC scored_VBD in_IN a_DT blinded_JJ
            fashion_NN with_IN regard_NN to_TO treatment_NN ._.
          
          
            RNA_NNP isolation_NN and_CC RNase_NNP protection_NN assay_NN
            Excised_NNP ankle_NN and_CC paw_NN joints_NNS were_VBD immediately_RB frozen_VBN
            in_IN liquid_JJ nitrogen_NN and_CC processed_VBN in_IN a_DT freezer_NN /_NN mill_NN
            (_( SPEX_NNP Certi-_NNP Prep_NNP ,_, Metuchen_NNP ,_, NJ_NNP ,_, USA_NNP )_) with_IN liquid_JJ
            nitrogen_NN at_IN 2_CD -_: minute_NN pulses_NNS ._. RNA_NNP was_VBD isolated_VBN from_IN 50_CD
            mg_NN of_IN the_DT joint_JJ powder_NN with_IN 1_CD ml_NN Trizol_NNP reagent_NN
            according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS (_( Gibco_NNP
            BRL_NNP ,_, Grand_NNP Island_NNP ,_, NY_NNP ,_, USA_NNP )_) ._. RNA_NNP was_VBD extracted_VBN with_IN 0_CD ._. 2_CD
            ml_NN chloroform_NN ,_, precipitated_VBD with_IN 0_CD ._. 5_CD ml_NN isopropyl_NN
            alcohol_NN ,_, and_CC resuspended_JJ in_IN 30_CD l_NN diethyl_NN
            pyrocarbonate-treated_JJ water_NN ._. Ten_CD micrograms_NNS of_IN total_JJ
            RNA_NNP from_IN each_DT sample_NN was_VBD used_VBN for_IN RNase_NNP protection_NN
            assay_NN (_( mCK_NN -_: 2_CD b_SYM and_CC -_: 3_CD b_SYM Multi-_NNP Probe_NNP Template_NNP Sets_NNP ,_,
            PharMingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, exposed_VBN to_TO a_DT Phosphor_NNP
            screen_NN ,_, and_CC quantified_VBN by_IN a_DT Phosphorimager_NNP with_IN the_DT use_NN
            of_IN Image_NN Quant_NN software_NN (_( Molecular_NNP Dynamics_NNP ,_, Sunnyvale_NNP ,_,
            CA_NNP ,_, USA_NNP )_) ._. The_DT signal-intensity_JJ ratio_NN of_IN different_JJ
            cytokine_NN messenger_NN RNA_NNP (_( mRNA_NN )_) to_TO GAPDH_NNP was_VBD
            determined_VBN ._.
          
        
      
    
  
